| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM200107263450401 |
| P698 | PubMed publication ID | 11474660 |
| P50 | author | Baruch Modan | Q4865865 |
| Patricia Hartge | Q28360431 | ||
| Sholom Wacholder | Q28360636 | ||
| Angela Chetrit | Q47460871 | ||
| P2093 | author name string | Eitan Friedman | |
| Flora Lubin | |||
| Galit Hirsh-Yechezkel | |||
| Joseph Menczer | |||
| Benjamin Piura | |||
| Gilad Ben-Baruch | |||
| Jeffery P. Struewing | |||
| Margaret A. Tucker | |||
| Uzi Beller | |||
| Amiram Fishman | |||
| Sara M. Ebbers | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 235-240 | |
| P577 | publication date | 2001-07-26 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation | |
| P478 | volume | 345 |
| Q30795103 | A Note on Penalized Regression Spline Estimation in the Secondary Analysis of Case-Control Data |
| Q37697518 | A general regression framework for a secondary outcome in case-control studies |
| Q82349672 | A policy approach to the development of molecular diagnostic tests |
| Q30431721 | A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study |
| Q81725988 | A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes |
| Q30423597 | Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer |
| Q36978323 | Analysis of case-control studies of genetic and environmental factors with missing genetic information and haplotype-phase ambiguity |
| Q78439258 | Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype |
| Q39699496 | Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers |
| Q44945619 | Assessing and managing breast cancer risk: clinical tools for advising patients. |
| Q53506544 | BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. |
| Q44221699 | BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases |
| Q38077900 | BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia |
| Q36315223 | BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses |
| Q34970470 | BRCA1: mechanisms of inactivation and implications for management of patients |
| Q35687632 | Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review |
| Q35039478 | Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. |
| Q34568554 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q36754871 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation |
| Q28756441 | Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology |
| Q37232123 | Critical molecular abnormalities in high-grade serous carcinoma of the ovary |
| Q81746827 | Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer |
| Q35675838 | Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations |
| Q36178261 | Endometrial and ovarian cancer in lynch syndrome |
| Q40351114 | Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients |
| Q43602602 | Exploiting gene-environment independence for analysis of case-control studies: an empirical Bayes-type shrinkage estimator to trade-off between bias and efficiency |
| Q78756600 | Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH |
| Q92367549 | Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer |
| Q83419012 | Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer |
| Q33620683 | Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers |
| Q93032475 | Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study |
| Q37105541 | Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort |
| Q34159997 | Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. |
| Q83525183 | Hereditary breast and ovarian cancer syndrome |
| Q38067433 | Hereditary gynaecological malignancies: advances in screening and treatment |
| Q36884728 | Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis |
| Q35934068 | Hereditary ovarian cancer in Ashkenazi Jews |
| Q37585309 | Hereditary ovarian cancer: biology, response to chemotherapy and prognosis |
| Q34120493 | Hormonal contraception and risk of cancer. |
| Q79464094 | Hormones and genetics caught in the crossfire of preventive medicine |
| Q35828679 | Improved survival in BRCA2 carriers with ovarian cancer |
| Q42574468 | Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk |
| Q46256306 | Influence of selected hormonal and lifestyle factors on familial propensity to ovarian cancer. |
| Q34580741 | Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk |
| Q40309521 | International patterns and trends in ovarian cancer incidence, overall and by histologic subtype |
| Q37306209 | Invited commentary: efficient testing of gene-environment interaction |
| Q57560381 | Long-term effects of oral contraceptives on ovarian cancer risk |
| Q36849977 | Management updates for women with a BRCA1 or BRCA2 mutation |
| Q33845209 | Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis |
| Q35084790 | Modifiers of risk of hereditary breast and ovarian cancer |
| Q34121226 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q34821475 | Noncontraceptive health benefits of oral contraceptives |
| Q48085053 | Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. |
| Q45300626 | On the interpretation, robustness, and power of varieties of case-only tests of gene-environment interaction. |
| Q74308244 | One gene and one outcome? No way |
| Q35808372 | Online tool to guide decisions for BRCA1/2 mutation carriers |
| Q37594378 | Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry |
| Q36696565 | Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations |
| Q34216239 | Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. |
| Q34476733 | Oral contraceptives: an update on health benefits and risks. |
| Q34273433 | Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies |
| Q35552356 | Ovarian cancer and high-risk women—implications for prevention, screening, and early detection |
| Q31147531 | Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls |
| Q36201263 | Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies |
| Q33327308 | Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism |
| Q80235342 | Ovarian cancer: an update |
| Q35015104 | Ovarian mass--benign or malignant? |
| Q46141034 | Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel |
| Q93130750 | Posttraumatic Stress Disorder Is Associated with Increased Risk of Ovarian Cancer: A Prospective and Retrospective Longitudinal Cohort Study |
| Q35155614 | Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update |
| Q81401953 | Primary peritoneal carcinoma--Uterine involvement and hysterectomy |
| Q44487666 | Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations |
| Q35069343 | Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer |
| Q57137351 | Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect |
| Q34920036 | Reproductive hormones and cancer: ovarian and colon cancer |
| Q57908386 | Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study |
| Q36824748 | Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors |
| Q34811314 | Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations |
| Q34575924 | Risk of cancer development in relation to oral contraception |
| Q44980624 | Robust discovery of genetic associations incorporating gene-environment interaction and independence |
| Q30620817 | Robust estimation for homoscedastic regression in the secondary analysis of case-control data |
| Q33760464 | Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study |
| Q31112039 | Semiparametric Bayesian analysis of case-control data under conditional gene-environment independence |
| Q49726138 | Semiparametric analysis of complex polygenic gene-environment interactions in case-control studies. |
| Q27009306 | Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer |
| Q24654487 | Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers |
| Q28082828 | Targeted immune therapy of ovarian cancer |
| Q47636257 | The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers |
| Q56508831 | The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews |
| Q37453854 | The contribution of BRCA1 and BRCA2 to ovarian cancer |
| Q30240709 | The disparate origins of ovarian cancers: pathogenesis and prevention strategies. |
| Q44507670 | The effect of hysterectomy on survival of patients with borderline ovarian tumors |
| Q35959353 | The genetic epidemiology of breast cancer genes |
| Q37613407 | The immune system in the pathogenesis of ovarian cancer |
| Q33206388 | The impact of a reduced fertility rate on women's health |
| Q34425538 | The semiparametric case-only estimator |
| Q92832186 | The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries |
| Q34783837 | Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study |
| Q90096220 | Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review |
| Q44071332 | Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel |
| Q35991381 | Using shared genetic controls in studies of gene-environment interactions |
| Q36348291 | Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women. |
| Q34167079 | Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy |
Search more.